Showing results (321-330 of 481) with videos related to
Sort By:
Pageof 49
Kidney Diseases (Basel, Switzerland)|November 27, 2019
A Global Evolutionary Trend of the Frequency of Primary Glomerulonephritis over the Past Four DecadesKeng Thye Woo, Choong Meng Chan, Cynthia Lim, et al.Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.Blood|August 9, 2023
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group studyBrent L Wood, Meenakshi Devidas, Ryan J Summers, et al.Blood|July 1, 2015
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232Michael J Borowitz, Brent L Wood, Meenakshi Devidas, et al.Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.Future Oncology (London, England)|March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignanciesAndrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.JCI Insight|July 27, 2018
Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomesJasmine C Wong, Victoria Bryant, Tamara Lamprecht, et al.Pageof 49